Beranda › Kanker Hipofaring › Michigan
Uji klinis Kanker Hipofaring di Michigan
5 studi untuk Kanker Hipofaring mencari peserta di lokasi di Michigan.
Kota di Michigan
Teks studi resmi (Bahasa Inggris)
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- dan 8 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06589804BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- University of Michigan Rogel Cancer Center, Ann Arbor
- Bronson Battle Creek, Battle Creek
- dan 23 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05136196Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- dan 60 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT02734537Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- McLaren Cancer Institute-Bay City, Bay City
- McLaren Cancer Institute-Clarkston, Clarkston
- Wayne State University/Karmanos Cancer Institute, Detroit
- dan 8 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06532279Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Henry Ford Cancer Institute, Detroit
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT04198766Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.